

Ketamine Hydrochloride Injection, USP

ISSUED 08/18/98

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION
-----MATERIAL NAME: Ketamine Hydrochloride Injection, USP
List Number: 2051, 2053MANUFACTURER: Hospital Products Division
Abbott Laboratories
Abbott Park. Illinois 60064EMERGENCY TELEPHONE NUMBER: 1-847-937-7970
CHEMTREC TELEPHONE NUMBER: 1-800-424-93002. COMPOSITION/INFORMATION ON INGREDIENTS
-----INGREDIENT NAME: Ketamine Hydrochloride *
CAS/RTECS NUMBERS: 1867-66-9 / GW1400000
OSHA-PEL 8HR TWA: N/L
STEL: N/L
CEILING: N/L
ACGIH-TLV 8HR TWA: N/L
STEL: N/L
CEILING: N/L
OTHER 8HR TWA: 1 mg/m3 (Abbott Laboratories)
LIMITS STEL: 4 mg/m3 (Abbott Laboratories)
CEILING: N/A

* Hazardous per OSHA criteria

3. HAZARDS INFORMATION

EMERGENCY OVERVIEW: In clinical use, this material is used as a non-barbiturate anesthetic. The active ingredient, ketamine hydrochloride is toxic by inhalation, ingestion and by skin contact. Target organs are the central nervous system, skin, eyes, respiratory tract, gastrointestinal tract and possibly the fetus.

ROUTE(S) OF ENTRY: Skin: Unlikely
Inhalation: Unlikely
Ingestion: Unlikely

Ketamine Hydrochloride Injection, USP

ISSUED 08/18/98

3. HAZARDS INFORMATION, continued

INGESTION RATING: Possibly toxic

SKIN ABSORPTION RATING: Possibly toxic

INHALATION RATING: Possibly toxic

CORROSIVENESS RATING: N/D

SKIN CONTACT RATING: Possible irritant

SKIN SENSITIZATION RATING: N/D

EYE CONTACT RATING: Possible irritant

TARGET ORGANS: N/D. Central nervous system, skin, eyes, respiratory tract, gastrointestinal tract and possibly the fetus.

CARCINOGENICITY RATING: NTP: N/L IARC: N/L OSHA: N/L

ACGIH: N/L

None

SIGNS AND SYMPTOMS: N/D. Clinically, ketamine can cause hallucinations, confusion, irrational behavior, elevated blood pressure and pulse rate, double vision, rapid eye movement and gastrointestinal upset. Direct contact would cause skin and eye irritation. Exposure to dust, would cause respiratory irritation.

MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: N/D. Elevated blood pressure and heart condition. Pre-existing skin, eye, respiratory and gastrointestinal tract ailments. Possibly pregnancy.

4. FIRST AID MEASURES

EYES: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care as necessary.

Ketamine Hydrochloride Injection, USP

ISSUED 08/18/98

4. FIRST AID MEASURES, continued

SKIN: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care as necessary.

INGESTION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care as necessary.

INHALATION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care as necessary.

5. FIRE FIGHTING PROCEDURES

FLASH POINT: Non-flammable

FLASH POINT METHOD: N/A

LOWER EXPLOSIVE LIMIT(%): N/D

UPPER EXPLOSIVE LIMIT(%): N/D

AUTOIGNITION TEMPERATURE: N/A

FIRE & EXPLOSION HAZARDS: N/A

EXTINGUISHING MEDIA: Use media appropriate for primary cause of fire.

FIRE FIGHTING INSTRUCTIONS: Fire fighters should wear self-contained breathing apparatus, flame and chemical resistant clothing, boots and gloves.

6. ACCIDENTAL RELEASE MEASURES

SPILL OR RELEASE PROCEDURES: Absorb with suitable material and place into container for disposal in accordance with Section 13.

Ketamine Hydrochloride Injection, USP

ISSUED 08/18/98

7. HANDLING AND STORAGE

HANDLING: Protect from light.

STORAGE: Store at controlled room temperature of 15-30 deg. C (59-86 deg. F).

SPECIAL PRECAUTIONS: Protect from light.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

ENGINEERING CONTROLS: No special provisions are required under normal product use.

RESPIRATORY PROTECTION: Not needed during normal product use.

SKIN PROTECTION: If skin contact is likely, impervious gloves are recommended.

EYE PROTECTION: Not required during normal product use.

OTHER PROTECTION: N/D

9. PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE/PHYSICAL STATE: Clear, colorless to slightly yellow solution.

ODOR: N/D

BOILING POINT: Water (approx.)

MELTING/FREEZING POINT: Water (approx.)

VAPOR PRESSURE (mm Hg): N/D

VAPOR DENSITY (Air=1): N/D

EVAPORATION RATE: N/D

BULK DENSITY: N/D

SPECIFIC GRAVITY: Water (approx.)

SOLUBILITY: Highly soluble in water.

pH: 3.5 - 5.5

VISCOSITY: N/D

Ketamine Hydrochloride Injection, USP

ISSUED 08/18/98

10. STABILITY AND REACTIVITY

CHEMICAL STABILITY: Solutions may darken upon prolonged exposure to light. Darkening does not affect potency.

INCOMPATIBILITIES: N/D

HAZARDOUS DECOMPOSITION PRODUCTS: When heated to decomposition it emits very toxic fumes of Cl-, NOx and HCl.

HAZARDOUS POLYMERIZATION: N/D

11. TOXICOLOGICAL INFORMATION

ORAL TOXICITY: N/D. LD50 = 447-670 mg/kg in rats and mice. (ketamine hydrochloride).

DERMAL TOXICITY: N/D. Ketamine hydrochloride reported in EC as toxic (R24).

INHALATION TOXICITY: N/D. Ketamine hydrochloride reported in EC as Toxic (R23), and irritating to respiratory system (R37).

CORROSIVENESS: N/D

DERMAL IRRITATION: N/D. Ketamine hydrochloride reported in EC as irritating to skin (R38).

OCULAR IRRITATION: N/D. Ketamine hydrochloride reported in EC as irritating to eyes (R36).

DERMAL SENSITIZATION: N/D

SPECIAL TARGET ORGAN EFFECTS: N/D. Clinical use of ketamine reported to cause reversible central nervous system effects, elevated blood pressure and heart rate and gastrointestinal upset. Embryotoxicity, and renal, hepatic and cardiac injury in offspring observed in rats administered intraperitoneal dosages of 25-100 mg/kg/day.

CARCINOGENICITY INFORMATION: N/D

Ketamine Hydrochloride Injection, USP

ISSUED 08/18/98

12. ECOLOGICAL INFORMATION

ECOLOGICAL INFORMATION: N/D

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHODS: Dispose of in accordance with local, state and federal regulations.

14. TRANSPORTATION INFORMATION
-----DOT STATUS: Not Regulated
PROPER SHIPPING NAME: N/D
HAZARD CLASS: N/D
UN NUMBER: N/D
PACKING GROUP: N/D
REPORTABLE QUANTITY: N/DIATA/ICA0 STATUS: Not Regulated
PROPER SHIPPING NAME: N/D
HAZARD CLASS: N/D
UN NUMBER: N/D
PACKING GROUP: N/D
REPORTABLE QUANTITY: N/DIMO STATUS: Not Regulated
PROPER SHIPPING NAME: N/D
HAZARD CLASS: N/D
UN NUMBER: N/D
PACKING GROUP: N/D
REPORTABLE QUANTITY: N/D
FLASH POINT: Non-flammable15. REGULATORY INFORMATION

TSCA STATUS: N/A

CERCLA STATUS: N/A

Ketamine Hydrochloride Injection, USP

ISSUED 08/18/98

15. REGULATORY INFORMATION, continued

SARA STATUS: N/A

RCRA STATUS: N/A

PROP 65 (CA): N/A

16. OTHER INFORMATION

LEGEND: N/A = Not Applicable
N/D = Not Determined
N/L = Not Listed
L = Listed
C = Ceiling
S = Short-term
(R) = Registered Trademark of Abbott Laboratories
(TM) = Registered Trademark of Abbott Laboratories

The information and recommendations contained herein are based upon tests believed to be reliable. However, Abbott Laboratories does not guarantee their accuracy or completeness nor shall any of this information constitute a warranty, whether expressed or implied, as to the safety of the goods, the merchantability of the goods, or the fitness of the goods for a particular purpose. Adjustment to conform with actual conditions of usage may be required. Abbott Laboratories assumes no responsibility for results obtained or for incidental or consequential damages arising from the use of these data. No freedom from infringement of any patent, copyright or trademark is to be inferred.

APPROVED BY: DLF